Protalix BioTherapeutics (PLX) Free Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.78% |
| Dec 31, 2025 | 19.00% |
| Sep 30, 2025 | -2.68% |
| Jun 30, 2025 | 7.18% |
| Mar 31, 2025 | 5.25% |
| Dec 31, 2024 | 28.04% |
| Sep 30, 2024 | 24.00% |
| Jun 30, 2024 | 9.66% |
| Mar 31, 2024 | 19.94% |
| Dec 31, 2023 | 23.45% |
| Sep 30, 2023 | -20.06% |
| Jun 30, 2023 | 20.95% |
| Mar 31, 2023 | 19.60% |
| Dec 31, 2022 | -16.50% |
| Sep 30, 2022 | 2.88% |
| Jun 30, 2022 | 3.96% |
| Mar 31, 2022 | 7.13% |
| Dec 31, 2021 | 5.81% |
| Sep 30, 2021 | 9.13% |
| Jun 30, 2021 | 20.15% |
| Mar 31, 2021 | -1.43% |
| Dec 31, 2020 | -6.96% |
| Sep 30, 2020 | 18.06% |
| Jun 30, 2020 | -11.90% |
| Mar 31, 2020 | -2.77% |
| Mar 31, 2019 | 2.85% |
| Dec 31, 2018 | -33.28% |
| Sep 30, 2018 | 29.09% |
| Jun 30, 2018 | 1.64% |
| Mar 31, 2018 | 1.13% |
| Dec 31, 2017 | 61.81% |
| Sep 30, 2017 | -4.17% |
| Jun 30, 2017 | -21.83% |
| Mar 31, 2017 | -4.34% |
| Dec 31, 2016 | -0.41% |
| Sep 30, 2016 | 17.04% |
| Jun 30, 2016 | -14.69% |
| Mar 31, 2016 | -7.63% |
| Dec 31, 2015 | 10.03% |
| Sep 30, 2015 | 1.86% |